WG
PCRX icon

Winton Group’s Pacira BioSciences PCRX Stock Holding History

Winton Group’s Portfolio PCRX Stock Details PCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-102,668
Closed -$2.45M – 961
2025
Q2 		$2.45M Buy
+102,668
New +$2.59M 0.13% 214
2024
Q3 		– Sell
-95,266
Closed -$2.73M – 741
2024
Q2 		$2.73M Buy
+95,266
New +$2.71M 0.18% 102
2023
Q1 		– Sell
-13,173
Closed -$509K – 1044
2022
Q4 		$509K Buy
+13,173
New +$641K 0.03% 625
2021
Q4 		– Sell
-7,437
Closed -$416K – 1295
2021
Q3 		$416K Sell
7,437
-3,058
-29% -$176K 0.02% 951
2021
Q2 		$637K Sell
10,495
-3,080
-23% -$195K 0.03% 785
2021
Q1 		$951K Buy
13,575
+2,810
+26% +$201K 0.05% 498
2020
Q4 		$644K Sell
10,765
-6,632
-38% -$388K 0.05% 657
2020
Q3 		$1.05M Sell
17,397
-65,405
-79% -$3.8M 0.03% 806
2020
Q2 		$4.34M Sell
82,802
-61,022
-42% -$2.55M 0.11% 274
2020
Q1 		$4.82M Sell
143,824
-17,810
-11% -$740K 0.13% 265
2019
Q4 		$7.32M Buy
161,634
+117,039
+262% +$4.97M 0.1% 340
2019
Q3 		$1.7M Buy
+44,595
New +$1.78M 0.02% 633

Other funds holding PCRX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
DPCM
Doma Perpetual Capital Management Miami, Florida $372M AUM 14.96% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Winton Group's PCRX Position: Q3 2025 in Review

Winton Group sold out of Pacira BioSciences (PCRX) in Q3 2025, closing a stake of 102,668 shares — an estimated $2.45M sold.

Winton Group first reported a position in PCRX in Q3 2019 and held it in 12 quarters. The position peaked at $7.32M in Q4 2019. 239 funds tracked by Wall St. Rank hold PCRX as of Q3 2025.

  • Winton Group reported no remaining Pacira BioSciences position as of Q3 2025 after selling out during the quarter.
  • Winton Group sold 102,668 Pacira BioSciences shares in Q3 2025, an estimated $2.45M.
  • Winton Group first reported a position in Pacira BioSciences in Q3 2019 and held it in 12 quarters.
  • Winton Group's Pacira BioSciences position peaked at $7.32M in Q4 2019.
  • 239 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2025.

Based on Winton Group's 13F filing for Q3 2025, filed 13 Nov 2025.